Regeneron Pharma (REGN) survey shows Eylea franchise in 'good shape' - Piper Sandler

October 23, 2023 8:41 AM EDT Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $885.00 price target on Regeneron Pharma (NASDAQ: REGN) saying a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login